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Abstract
OBJECTIVE—We sought to evaluate the frequency of, and factors associated with, the use of 3 
evidence-based interventions: antenatal corticosteroids for fetal lung maturity, progesterone for 
prevention of recurrent preterm birth, and magnesium sulfate for fetal neuroprotection.
STUDY DESIGN—A self-administered survey was conducted from January through May 2011 
among obstetricians from 21 hospitals that included 30 questions regarding their knowledge, 
attitudes, and practice of the 3 evidence-based interventions and the 14-item short version of the 
Team Climate for Innovation survey. Frequency of use of each intervention was ascertained from 
an obstetrical cohort of women between January 2010 and February 2011.
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RESULTS—A total of 329 obstetricians (74% response rate) who managed 16,946 deliveries 
within the obstetrical cohort participated in the survey. More than 90% of obstetricians reported 
that they incorporated each intervention into routine practice. Actual frequency of administration 
in women eligible for the treatments was 93% for corticosteroids, 39% for progesterone, and 
71%formagnesiumsulfate. Provider satisfaction with quality of treatment evidence was 97% for 
corticosteroids, 82% for progesterone, and 57% for magnesium sulfate. Obstetricians perceived 
that barriers to treatment were most frequent for progesterone (76%), 30% for magnesium sulfate, 
and 17% for corticosteroids. Progesterone use was more frequent among patients whose provider 
reported the quality of the evidence was above average to excellent compared with poor to average 
(42% vs 25%, respectively; P < .001), and they were satisfied with their knowledge of the 
intervention (41%vs 28%; P = .02), and was less common among patients whose provider 
reported barriers to hospital or pharmacy drug delivery (31% vs 42%; P = .01). Corticosteroid 
administration was more common among patients who delivered at hospitals with 24 hours a day–
7 days a week maternal-fetal medicine specialist coverage (93% vs 84%; P = .046),
CONCLUSION—Obstetricians in Maternal-Fetal Medicine Units Network hospitals frequently 
use these evidence-based interventions; however, progesterone usewas found to be related to their 
assessment of evidence quality. Neither progesterone nor the other interventions were associated 
with overall climate of innovation within a hospital as measured by the Team Climate for 
Innovation. National Institutes of Health Consensus Conference Statements may also have an 
impact on use; there is such a statement for antenatal corticosteroids but not for progesterone for 
preterm prevention or magnesium sulfate for fetal neuroprotection.
Keywords
antenatal corticosteroids; evidence-based interventions; magnesium sulfate; Maternal-Fetal 
Medicine Units Network; progesterone
The translation of research into clinical practice is influenced by numerous factors that may 
facilitate or hinder its translation, including the quality of the evidence, methods of 
disseminating results, presence or absence of consensus statements, attitudes and behaviors 
of physicians, hospital climate, and costs. In an effort to improve on the translation of 
research into practice, the National Institutes of Health (NIH) created the Roadmap for 
Medical Research in 2002.1
Traditional methods of disseminating information on new treatments in the obstetrical 
community include continuing education activities, lectures, and grand rounds. These 
methods have been described as ineffective at changing complex practices.2 More recently it 
has been recognized that an organizational change, as well as individual provider 
knowledge, is needed to facilitate adoption of new treatments.3 The climate (hospital and 
team), the user (provider), and the intervention itself interact and affect the implementation 
process.4
The Eunice Kennedy Shriver National Institute of Child Health and Human Development 
(NICHD) Maternal-Fetal Medicine Units (MFMU) Network, along with many other 
perinatal researchers, has provided evidence for therapies that aim to benefit pregnant 
women and their children. However, little is known about why some of the obstetrical 
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evidence that has been produced is adopted and why some is not. We set out to evaluate 
factors associated with the adoption trends of 3 evidence-based obstetrical interventions at 
different stages of implementation within the MFMU Network hospitals. The interventions 
studied were antenatal corticosteroids injections for fetal lung maturity, progesterone 
injections for the prevention of recurrent preterm birth, and intravenous magnesium sulfate 
for cerebral palsy prevention.
Antenatal corticosteroids
Treatment of women at risk of preterm delivery before 34 weeks with antenatal 
corticosteroids is a widely accepted practice. Liggins and Howie5 first introduced this 
therapy in 1972. It was further supported by a metaanalysis in 19906 and an NIH Consensus 
Conference Statement in 1994.7 This was followed by a second NIH Consensus Conference 
Statement in 20008 to make recommendations on repeat courses of antenatal steroids.
Notably, there have been 3 metaanalyses further disseminating information on this topic. 
Namely, the Cochrane Collaboration in 2006,9 which was an extensive document to assess 
the effects of maternal antenatal corticosteroids on the mother, the fetus, the neonate, and the 
child; the Cochrane Collaboration in 2007,10 which evaluated the effectiveness and safety of 
repeat courses of corticosteorids; and the Cochrane Collaboration in 2008,11 which 
elaborated on the effects of various types and dosing regimens of corticosteroids.
Progesterone
Treating women who experienced a prior spontaneous delivery with progesterone in the 
current pregnancy has been studied over the past 3 decades. In 1975 Johnson et al12 
published one of the first randomized clinical trials on the topic and concluded that this 
therapy may be beneficial but that further studies and long-term follow-up are needed. In 
2003, 2 major randomized clinical trials revealed further support for this treatment. Da 
Fonseca et al13 published a report on the efficacy of vaginal progesterone in preventing 
recurrent preterm delivery, and Meis et al14 published the MFMU Network trial of 17α-
hydroxyprogesterone caproate injections, which showed a reduction in the risk of recurrent 
preterm deliveries.
Since then there have been several randomized clinical trials using various forms of 
progesterone delivery: vaginal gel,15 oral micronized gelatin capsules,16 vaginal micronized 
capsules,17 vaginal suppositories,18 and intramuscular agents,19 all of which showed some 
benefit to this therapy. Several systematic review articles and metaanalyses similarly 
concluded a reduced risk of recurrent preterm delivery with the use of progestogens.20-25 
The American College Of Obstetricians and Gynecologists Committee Opinion in 200826 
and subsequently the Practice Bulletin, Prediction and prevention of preterm birth,27 further 
supported this practice based on the evidence.
Magnesium sulfate
In 1992 Kuban et al28 published an epidemiological study to assess the perinatal risk factors 
associated with intraventricular hemorrhage in the newborn and found that mothers who 
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received magnesium sulfate had babies with a lower incidence of intraventricular 
hemorrhage. This was followed by a case-control study by Nelson and Grether29 in 1995 
showing that magnesium sulfate treatment is associated with a reduced risk of cerebral palsy 
among very low-birthweight infants.
Several observation studies were published since then, some showing benefit30-35 and some 
negating the benefit.36-43 These were followed by several randomized clinical trials44-48 and 
subsequent systematic reviews with a metaanalysis of eligible trials,49-51 which concluded 
that this therapy has a neuroprotective effect on the fetus. Despite additional support for this 
therapy from several clinical practice guideline documents and committee opinions,52-56 the 
optimal regimen for balancing effectiveness and adverse effects to the mother and fetus 
remained unclear.57
Materials and Methods
A survey was conducted among obstetricians from January 2011 through May 2011 at 21 
hospitals in the MFMU Network, and the survey data were linked to data abstracted from 
medical charts of deliveries occurring from January 2010 until February 2011, at the same 
21 hospitals, of patients delivered by the survey responders. The online, self-administered 
survey included questions regarding the responder’s knowledge of 3 obstetrical 
interventions, their satisfaction with the evidence, and the barriers to the use of these 
interventions.
The survey also included questions regarding the team climate at each hospital, ascertained 
using the validated 14 item short version of the Team Climate for Innovation (TCI) 
survey,58 which is based on West and Farr’s59 4 factor theory of group innovation with team 
activities.60 The TCI survey has been used to predict success or failure of quality 
improvement strategies in several countries and industries. Ouwens et al61 assessed the TCI 
survey in the health care industry among hospital teams and found it to be a valid, reliable, 
and discriminating self-report measure of team climate in hospital teams.
The 4 groups of questions in the TCI address vision (team members are committed to clear 
and realistic objectives), participative safety (team members interact in a participative and 
interpersonally nonthreatening climate), task orientation (team members are committed to 
high standards and are prepared for basic questions and apprised of weaknesses), and 
support for innovation (there is support for innovation attempts and cooperation to develop 
and apply new ideas).
To be eligible for the survey, providers had to be a general obstetrician or maternal-fetal 
medicine specialist and actively involved in patient deliveries at 1 of the 21 participating 
hospitals. Eligibility was ascertained from an obstetrical cohort (described below) of 
delivery data. The obstetrical cohort data were accessed to identify obstetrical providers who 
had a minimum of 5 deliveries in the cohort over a 6 month period (January 2010 through 
June 2010). From the initial list of 760 potentially eligible obstetricians, 467 providers were 
randomly chosen by the data coordinating center that assigned each a masked identification. 
These masked identifications along with a unique user name and password were 
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incorporated in a cover letter that explained the purpose and anonymous nature of the survey 
and that completion of the survey would be considered consent for study participation. The 
institutional review board at each participating institution approved the study.
The proportion of patients eligible for the 3 treatments of interest and the proportion of 
eligible patients who actually received the treatment were ascertained for each obstetrician 
using the Assessment of Perinatal Excellence (APEX) study62 conducted by the Eunice 
Kennedy Shriver NICHD MFMU network. The APEX study was designed to develop 
quality measures for intrapartum obstetrical care and was approved by the institutional 
review board at each participating institution under a waiver of informed consent. Full 
details of the study design have been previously published.62
For this analysis, only patients who were delivered by one of the attending providers 
participating in the survey were included. For each treatment being studied, we identified all 
patients eligible to receive the treatment. We defined women eligible for receiving antenatal 
corticosteroids as those who delivered on the labor and delivery floor at less than 34 weeks’ 
gestation and delivered 4 or more hours after admission. Women eligible for progesterone 
were thosewho delivered on the labor and delivery floor with a singleton pregnancy, had a 
history of a pretermbirth in a prior pregnancy, had at least 2 prenatal care visits, and had a 
pregnancy that was dated by a first- or second-trimester ultrasound or had assisted 
reproductive technology (as a proxy of receiving prenatal care before the third trimester). 
Among the women meeting these initial criteria for eligibility of progesterone, if 
progesterone was received, the previous pregnancy was assumed to have been spontaneous 
(the population eligible for progesterone); otherwise, the prenatal records were reabstracted 
to determine whether the previous preterm birth was spontaneous and to determine whether 
the patient received progesterone. Women eligible formagnesiumsulfatewere thosewithout 
gestational hypertension or preeclampsia (because they may receive magnesium sulfate for 
seizure prophylaxis), who delivered on the labor and delivery floor before 32 weeks of 
gestation, and who delivered 4 or more hours after admission. Within each subcohort of 
women eligible for the treatment under study, the primary outcomewas whether the patient 
received the treatment.
Data were analyzed at the patient level. The χ2 test or the Fisher exact test, when 
appropriate, was used to assess univariate differences. Multivariable analysis was used to 
determine which patient, attending physician, and hospital factors were independently 
associated with the use of each of the interventions. Model selection and internal validation 
was performed using k-fold cross-validation in which the cohort was randomly divided into 
10 equal parts and logistic regression models, using backward selection, were generated 
using every possible combination of 9 of the 10 sets.63 Variables with P < .05 were retained, 
and each of the 10 subsamples was used for validation. All tests were 2 tailed and P < .05 
was used to denote statistical significance. No imputation for missing data was performed 
and no adjustments were made for multiple comparisons.64 Analyses were performed using 
SAS software (SAS Institute Inc, Cary, NC).
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The majority of hospitals that participated in this study were teaching hospitals (19 of 21) 
and located in an urban setting (19 urban, 2 suburban, and 0 rural of 21). Most of the 
hospitals had 24 hours a day, 7 days a week availability of maternal-fetal medicine 
specialists (19 of 21), in-house obstetric attending physician (laborist or otherwise) (18 of 
21), neonatology services (17 of 21), and obstetric anesthesia services (18 of 21).
The median number of deliveries captured in APEX at the study hospitals was 4074. Of the 
467 randomly selected providers, 443 remained eligible (ie, still delivering at the hospital at 
the time the survey was implemented), and 329 of the 443 (74%) completed the survey. 
Almost all invited maternal-fetal medicine specialists participated in the survey (92%), and 
the majority of obstetricians participated (70%). The 329 participating obstetricians 
performed 16,946 of the deliveries in the APEX observational cohort.
The patient characteristics of those cared for by physicians participating in the survey, 
compared with those whose physicians remained eligible but did not respond or refused 
participation in the survey, differed (Table 1). APEX patients included in this study were 
more ethnically diverse, more high risk, more likely to have been delivered by a maternal-
fetal medicine specialist, more likely delivered at a teaching hospital, and more likely to 
have used magnesium sulfate if eligible for that treatment, compared with APEX patients 
delivered by an obstetrician who did not respond or refused participation in the survey.
Table 2 describes the providers’ satisfaction with their knowledge about the treatment, their 
satisfaction with the evidence for each treatment, and the actual frequency of each treatment. 
More than 90% of the providers reported incorporating each of the treatments into practice. 
Actual use in eligible patients was high for antenatal corticosteroids (93%), but it was 71% 
for the magnesium sulfate and only 39% for the progesterone treatment. Provider 
satisfaction with quality of treatment evidence was 97% for antenatal corticosteroids, 82% 
for progesterone, and 57% for magnesium sulfate. Providers were asked whether barriers 
existed that prevented better use of the interventions. Seventy-six percent of providers 
reported barriers for progesterone, 30% for magnesium sulfate, and 17% for antenatal 
corticosteroids. Specific barriers cited are presented in Table 2.
Table 3 presents the frequency of eligible patients receiving each of the interventions by 
physician and hospital characteristics. Patients in hospitals with a maternal-fetal medicine 
specialist available 24 hours a day, 7 days a week were more likely to receive antenatal 
corticosteroid treatment.
Table 4 presents the frequency of receiving treatment, among eligible patients, by 
obstetrician provider attitudes regarding the treatments and hospital climate. Patients whose 
providers reported that they were more likely to use the intervention in practice had greater 
frequency of actual progesterone and magnesium sulfate treatment. Patients whose provider 
rated the quality of the evidence for a given practice as above average to excellent had 
greater frequency of treatment only for progesterone treatment. In addition, progesterone 
treatment was more common if providers were satisfied with their knowledge of the 
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intervention and was less common if the provider reported a barrier to hospital or pharmacy 
drug delivery.
Reported quality of the evidence and barriers to hospital or pharmacy drug delivery 
remained significantly associated with progesterone use in multivariable models (Table 5). 
Progesterone treatment was lowest among the uninsured/self-pay patients (Table 5). 
Maternal-fetal medicine coverage was no longer significantly associated with antenatal 
corticosteroid treatment in multivariable analysis (Table 5). Patients presenting with preterm 
premature rupture of membranes were slightly less likely to have received antenatal steroids, 
which is a treatment prescribed over a 24 hour period. None of the provider attitudes was 
associated with magnesium sulfate. Uninsured/self-pay patients were more likely to have 
received magnesium sulfate. No association with frequency of use was observed for TCI 
scores.
Comment
We evaluated factors that affect how clinical research is translated into practice in the setting 
of obstetrical care among MFMU Network hospitals. Our results suggest that the adoption 
of 3 evidence-based obstetrical interventions was found to be related to providers’ 
assessment of evidence quality but not to the overall climate of innovation within a hospital 
as measured by the TCI.
For innovation to occur in a health care setting, providers need to be knowledgeable in 
evidence-based practice, satisfied with the evidence for a given practice, and capable of 
implementing a change.65,66 The nature of the innovation also plays a key factor in its 
adoption.3
Physicians perceived some barriers to their patients receiving treatment, and these may also 
affect use of interventions. Difficulty in hospital/pharmacy drug delivery was significantly 
associated with the use of progesterone, which was used in only 39% of eligible patients. 
The cost of progesterone treatment, once approved by the Food and Drug Administration 
(FDA) in February 2011, rose substantially from $20 to $1500 per injection.67 Outrage from 
the obstetrical community and patients forced the company to reduce its price and offer 
financial assistance programs.68
Additionally, the FDA issued a statement to facilitate the continued manufacturing of this 
product by compounding pharmacies in March 201169 but later cautioned against the purity 
and potency of compounding these products.70 The physician survey was conducted 
between January 2011 and May 2011 in the midst of this confusion with drug availability 
and recommendations. Anecdotally, during chart review the nurse abstractors noted that 
many patients were offered progesterone but declined because of the cost and/or lack of 
coverage by their insurance. We acknowledge that the lack of clear proportion of those who 
declined treatment because of cost is a limitation of this study. The cost barrier is less likely 
to have affected the other 2 interventions that are usually accepted by payers as part of the 
inpatient care.
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There was no difference in the frequency of implementation among large-delivery volume 
and small-delivery volume hospitals. This was surprising because hospital volume is 
reported to affect the hospital climate for innovation, with larger-delivery volumes thought 
to be more conducive to change.71
In contrast to studies in other disciplines, 58,61,72,73 we found that the hospital climate did 
not affect the use of different interventions. We are uncertain of the reasons for this 
discrepancy in results.
The maturity of these 3 interventions varies and may also contribute to their adoption and 
use. Antenatal steroid evidence is more than 10 years old, progesterone is 5-10 years old, 
and magnesium sulfate is less than 5 years old. More important than maturity, however, may 
be the quality of the evidence. The quality of the evidence as perceived by the providers was 
highest for antenatal steroids and lowest for magnesium sulfate, but this factor was 
significantly associated only with the use of progesterone.
In this study, eligibility for an intervention was defined in a way that did not take into 
consideration all clinical scenarios faced by the attending physician, and physicians’ 
perceived eligibility, need, and likely benefit may be more refined at the individual patient 
level.
In the medical profession, leadership opinion and consensus statements affect widespread 
use. It is possible that NIH Consensus Conference Statements on utilization of obstetric 
interventions have a greater impact than press releases. The evidence for antenatal steroids 
was available since 1972, but its utilization increased significantly in the United States only 
after the NIH Consensus Conference Statement in 1994. Whereas there have been NICHD 
press releases and American College of Obstetricians and Gynecologists Committee 
Opinions for the use of progesterone to reduce preterm birth and magnesium sulfate for 
neuroprophylaxis, there were no NIH Consensus Conference Statements.
Because this is a survey study, it is affected by recall or responder bias. It may have been 
hard for some survey responders to recall information or to tell the truth about a 
controversial question. Surveys are not ideal for capturing exceptions and controversial 
issues as would a face-to-face interview or focus group, but the opposite can be true as well. 
Surveys have an inherent inflexible design because the questions are more general and may 
not apply to each provider. The strength of our survey study is being able to correlate the 
actual use of the 3 interventions by the same providers who responded to the survey. 
However, use of these 3 interventions was specific to the MFMU Network, and the majority 
of providers that participated in the survey were MFM specialists.
Clinical implications
This study demonstrates some factors that can facilitate adoption of evidence-based 
interventions, but many questions remain. We recommend continued efforts to evaluate the 
evidence, to disseminate the evidence superlatively such as through NIH Consensus 
Statements, and to remove barriers to implementation.
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TABLE 1
Patient and delivery characteristics by provider survey participation
Characteristics of the study population
Delivered by an obstetrician 
who participated in the 
survey (n = 16,946), n (%)
Delivered by an obstetrician 
who refused participation in 
the survey (n = 4525), n (%) P value
Age, y < .001
 <20 1355 (8.0) 267 (5.9)
 20–34.9 12,728 (75.1) 3617 (79.9)
 ≥35 2863 (16.9) 641 (14.2)
Race/ethnicitya < .001
 Non-Hispanic white 6814 (40.2) 3025 (66.9)
 Non-Hispanic black 3893 (23.0) 539 (11.9)
 Non-Hispanic Asian 1067 (6.3) 195 (4.3)
 Hispanic 4066 (24.0) 625 (13.8)
 Other or not documented 1106 (6.5) 141 (3.1)
Insurance status < .001
 Uninsured or self-pay 1983 (11.8) 315 (7.0)
 Government assisted 7383 (43.7) 1155 (25.6)
 Private 7513 (44.5) 3043 (67.4)
Prenatal care 15,642 (97.7) 4273 (98.6) < .001
Multiple gestation 476 (2.8) 98 (2.2) .02
Premature rupture of the membranes 917 (5.5) 171 (3.8) < .001
Eligible for ACSb 500 (3.0) 96 (2.1) .003
 ACS use among those eligible for ACS 463 (92.6) 84 (87.5) .10
Eligible for PROGc 753 (4.4) e
Eligible for MGd 181 (1.1) 35 (0.8) .08
 MG use among those eligible for MG 129 (71.3) 13 (37.1) < .001
Gestational age at delivery, wks (first born in multifetal) < 001
 230 to 336 859 (5.1) 146 (3.2)
 340 to 366 1448 (8.5) 343 (7.6)
 370 to 416 14,600 (86.2) 4029 (89.0)
 ≥420 39 (0.2) 7 (0.2)
Specialty of patient’s attending at delivery < .001
 General obstetrics 12,717 (75.0) 4392 (97.1)
 Maternal-fetal medicine 4229 (25.0) 133 (2.9)
Years since patient’s attending physician at delivery graduated 
medical or midwifery school
< .001
 0–9.9 (includes no attending at delivery) 3443 (20.6) 499 (11.0)
 10–14.9 3553 (21.3) 657 (14.5)
 15–19.9 3225 (19.3) 804 (17.8)
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Characteristics of the study population
Delivered by an obstetrician 
who participated in the 
survey (n = 16,946), n (%)
Delivered by an obstetrician 
who refused participation in 
the survey (n = 4525), n (%) P value
 20–24.9 2580 (15.5) 779 (17.2)
 ≥25 3878 (23.3) 1786 (39.5)
Maternal-fetal medicine availability 24/7 14,045 (82.9) 3671 (81.1) .006
Obstetrics residents on labor and delivery 16,413 (96.9) 3788 (83.7) < .001
ACS, antenatal corticosteroids for fetal lung maturity; MG, magnesium sulfate for fetal neuroprotection; PROG, progesterone for prevention of 
preterm delivery.
a
Race/ethnicity was reported in the chart;
b
Patients eligible for antenatal corticosteroid for fetal lung maturity were those who delivered in the labor and delivery department before 34 weeks 
of gestation and delivered 4 or more hours after admission;
c
Patients eligible for progesterone for the prevention of preterm birth were those who delivered in the labor and delivery department with a 
singleton pregnancy, with a history of a prior spontaneous preterm delivery, who had at least 2 prenatal care visits, and whose pregnancy was dated 
by a first- or second-trimester ultrasound or had assisted reproductive tech- nology;
d
Patients eligible for magnesium sulfate for neuroprotection were those who delivered in the labor and delivery department before 32 weeks of 
gestation, did not have gestational hypertension or preeclampsia, and delivered 4 or more hours after admission;
e
Not determined in this group.
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TABLE 2








preterm birth, n 
(%)
Magnesium sulfate for 
neuroprotection, n (%)
Provider stated that they prescribe intervention in practice 
(intent)
16,812 (99.2) 16,375 (96.6) 15,490 (91.4)
Provider was satisfied with their knowledge of the intervention 16,373 (96.6) 14,292 (84.4) 11,126 (65.7)
Provider rated the quality of the evidence for the intervention as 
above average to excellent
16,446 (97.1) 13,788 (81.6) 9528 (57.4)
Provider perceived barriers to their patients’ receiving the 
intervention
2875 (17.1) 12,913 (76.4) 4996 (30.1)
 Financial 142 (0.8) 7408 (43.8) 100 (0.6)
 Fear of birth defects 536 (3.2) 1430 (8.5) 236 (1.4)
 Fear of side effects a a 3945 (23.7)
 Fear of injections 1440 (8.6) 6929 (41.0) a
 Difficulty with hospital or pharmacy drug delivery 272 (1.6) 4185 (24.8) 74 (0.4)
 Difficulty arranging injection a 4250 (25.1) a
 Poor compliance 531 (3.2) 3588 (21.2) a
 Poor patient understanding of drug benefits 791 (4.7) 2322 (13.7) 2184 (13.1)
Actual frequency of treatment in patients eligible for the 
treatment (practice)
463 (92.6) 292 (38.8) 129 (71.3)
a
The survey did not ascertain this information for this particular intervention.
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TABLE 3
Receiving treatment by characteristics of the provider and hospital
Variable
Antenatal corticosteroid 
for fetal lung maturity (n = 
500 eligible),a n (%)
Progesterone for 
prevention of preterm 
birth (n = 753 eligible),b 
n (%)
Magnesium sulfate for 
neuroprotection (n = 181 
eligible),c n (%)
Hospital annual delivery volume
 Tertile 1 225 (92.6) 110 (36.2) 53 (68.0)
 Tertile 2 162 (92.6) 118 (44.7) 55 (72.4)
 Tertile 3 76 (92.7) 64 (34.6) 21 (77.8)
Hospital availability of maternal-fetal medicine 
24/7
 No 31 (83.8)d 48 (47.1) 8 (61.5)
 Yes 432 (93.3)d 244 (37.5) 121 (72.0)
Attending specialty
 General obstetrics 221 (91.3) 179 (38.2) 60 (69.8)
 Maternal-fetal medicine 242 (93.8) 113 (39.8) 69 (72.6)
Attending years since graduated medical 
school
 0–9.9 (includes no attending at delivery) 102 (93.6)d 56 (38.9) 31 (73.8)
 10–14.9 113 (96.6)d 70 (40.9) 32 (65.3)
 15–19.9 94 (94.0)d 50 (36.5) 23 (74.2)
 20–24.9 37 (78.7)d 35 (35.4) 8 (72.7)
 ≥25 115 (92.0)d 77 (40.3) 34 (72.3)
a
Patients eligible for antenatal corticosteroid for fetal lung maturity were those who delivered in the labor and delivery department before 34 weeks 
of gestation and delivered 4 or more hours after admission;
b
Patients eligible for progesterone for the prevention of preterm birth were those who delivered in the labor and delivery department with a 
singleton pregnancy, with a history of a prior spontaneous preterm delivery, who had at least 2 prenatal care visits, and whose pregnancy was dated 
by a first- or second-trimester ultrasound or had assisted reproductive technology;
c
Patients eligible for magnesium sulfate for neuroprotection were those who delivered in the labor and delivery department before 32 weeks of 
gestation, did not have gestational hypertension or pre-eclampsia, and delivered 4 or more hours after admission;
d
Statistically significant χ2 or Fisher exact test (P < .05).
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TABLE 4
Receiving treatment by provider attitudes and hospital climate
Variable
Antenatal 
corticosteroid for fetal 
lung maturity (n = 500 
eligible),a n (%)
Progesterone for 
prevention of preterm 
birth (n = 753 
eligible),b n (%)
Magnesium sulfate for 
neuroprotection (n = 181 
eligible),c n (%)
Provider stated that they prescribe intervention in 
practice (intent)
 No 2 (66.7) 3 (10.3)d 3 (37.5)d
 Yes 461 (92.8) 289 (39.9)d 126 (72.8)d
Provider was satisfied with their knowledge of the 
intervention
 No 27 (100.0) 29 (28.4)d 30 (65.2)
 Yes 436 (92.2) 263 (40.5)d 99 (73.3)
Provider rated the quality of the evidence for the 
intervention as above average to excellent
 No 7 (87.5) 35 (24.5)d 53 (69.7)
 Yes 456 (92.7) 257 (42.3)d 75 (72.1)
Provider perceived barriers to their patients’ receiving 
the intervention
 No 398 (92.1) 56 (35.2) 93 (73.2)
 Yes 63 (95.5) 236 (39.9) 33 (66.0)
 Financial
  No 461 (92.6) 143 (36.3) 125 (71.0)
  Yes 0 (0.0) 149 (41.9) 1 (100.0)
 Fear of birth defects
  No 457 (92.7) 263 (38.0) 126 (71.2)
  Yes 4 (80.0) 29 (50.9) 0 (0.0)
 Fear of side effects
  No e e 99 (73.3)
  Yes e e 27 (64.3)
 Fear of injections
  No 439 (92.4) 173 (40.9) e
  Yes 22 (95.7) 119 (36.4) e
 Difficulty with hospital or pharmacy drug delivery
  No 454 (92.7) 235 (41.5)d 126 (71.2)
  Yes 7 (87.5) 57 (31.0)d 0 (0.0)
 Difficulty arranging injection
  No e 222 (40.3) e
  Yes e 70 (35.2) e
 Poor compliance
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Variable
Antenatal 
corticosteroid for fetal 
lung maturity (n = 500 
eligible),a n (%)
Progesterone for 
prevention of preterm 
birth (n = 753 
eligible),b n (%)
Magnesium sulfate for 
neuroprotection (n = 181 
eligible),c n (%)
  No 440 (92.2) 231 (39.5) e
  Yes 21 (100.0) 61 (37.0) e
Poor patient understanding of drug benefits
  No 445 (92.5) 254 (39.6) 112 (70.4)
  Yes 16 (94.1) 38 (34.9) 14 (77.8)
Team Climate Inventory score
 Quartile 1 90 (93.8) 56 (33.7) 23 (69.7)
 Quartile 2 104 (95.4) 81 (44.8) 26 (63.4)
 Quartile 3 127 (90.7) 73 (39.9) 40 (76.9)
 Quartile 4 120 (90.2) 72 (38.3) 33 (71.7)
a
Patients eligible for antenatal corticosteroid for fetal lung maturity were those who delivered in the labor and delivery department before 34 weeks 
of gestation and delivered 4 or more hours after admission;
b
Patients eligible for progesterone for the prevention of preterm birth were those who delivered in the labor and delivery department with a 
singleton pregnancy, with a history of a prior spontaneous preterm delivery, who had at least 2 prenatal care visits, and whose pregnancy was dated 
by a first- or second-trimester ultrasound or had assisted reproductive technology;
c
Patients eligible for magnesium sulfate for neuroprotection were those who delivered in the labor and delivery department before 32 weeks of 
gestation, did not have gestational hypertension or preeclampsia, and delivered 4 or more hours after admission;
d
Statistically significant χ2 or Fisher exact test (P < .05);
e
The survey did not ascertain this information for this particular intervention.
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TABLE 5
Multivariable models for factors associated with receiving treatment
Variable
Antenatal corticosteroid 
for fetal lung maturity (n 
= 500 eligible),a RR (CI)
Progesterone for 
prevention of preterm 
birth (n = 753 eligible),b 
RR (CI)
Magnesium sulfate for 
neuroprotection (n = 
181 eligible),c RR (CI)
Insurance status
 Uninsured or self-pay 0.27 (0.14–0.51) 1.34 (1.03–1.75)
 Government assisted 0.72 (0.52–1.01) 1.20 (0.97–1.49)
 Private 1.00 (referent) 1.00 (referent)
Preterm premature rupture of the membranes 0.93 (0.88–0.99)
Attending years since graduated medical school
 0–9.9 (includes no attending at delivery) 1.00 (referent)
 10–14.9 1.02 (0.97–1.08)
 15–19.9 1.01 (0.95–1.07)
 20–24.9 0.84 (0.72–0.98)
 ≥25 0.99 (0.92–1.05)
Provider rated the quality of the evidence for the 
intervention as above average to excellent
2.38 (1.56–3.63)
Difficulty with hospital or pharmacy drug delivery 0.57 (0.40–0.83)
CI, confidence interval; RR, relative risk.
a
Patients eligible for antenatal corticosteroid for fetal lung maturity were those who delivered in the labor and delivery department before 34 weeks 
of gestation and delivered 4 or more hours after admission;
b
Patients eligible for progesterone for the prevention of preterm birth were those who delivered in the labor and delivery department with a 
singleton pregnancy, with a history of a prior spontaneous preterm delivery, who had at least 2 prenatal care visits, and whose pregnancy was dated 
by a first or second trimester ultrasound or had assisted reproductive technology;
c
Patients eligible for magnesium sulfate for neuroprotection were those who delivered in the labor and delivery department before 32 weeks of 
gestation, did not have gestational hypertension or pre-eclampsia, and delivered 4 or more hours after admission.
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